

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM758767

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
RubiconMD, Inc.		09/30/2022	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Hercules Capital, Inc., as Agent		
Street Address:	400 Hamilton Avenue		
Internal Address:	Suite 310		
City:	Palo Alto		
State/Country:	CALIFORNIA		
Postal Code:	94301		
Entity Type:	Corporation: MARYLAND		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Registration Number:	6152085	RUBICONMD	
Registration Number:	5820852	CLINICAL TRANSFORMATION IN TECHNOLOGY	
Serial Number:	97322231	BHCARE	
Serial Number:	97322197	ECONSULT+	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	(619) 699-2708		
Email:	christian.cruz@us.dlapiper.com		
Correspondent Name:	DLA Piper LLP (US)		
Address Line 1:	401 B Street		
Address Line 2:	Suite 1700		
Address Line 4:	San Diego, CALIFORNIA 92101		
NAME OF SUBMITTER:	Matt Schwartz		
SIGNATURE:	/s/ Matt Schwartz		
DATE SIGNED:	10/03/2022		
Total Attachments: 8			

CH \$115.00 6152085

source=Hercules Capital - Oak Street Health_ Inc. - Intellectual Property Security Agreement - RubiconMD, Inc#page1.tif

source=Hercules Capital - Oak Street Health_ Inc. - Intellectual Property Security Agreement - RubiconMD, Inc#page2.tif

source=Hercules Capital - Oak Street Health_ Inc. - Intellectual Property Security Agreement - RubiconMD, Inc#page3.tif

source=Hercules Capital - Oak Street Health_ Inc. - Intellectual Property Security Agreement - RubiconMD, Inc#page4.tif

source=Hercules Capital - Oak Street Health_ Inc. - Intellectual Property Security Agreement - RubiconMD, Inc#page5.tif

source=Hercules Capital - Oak Street Health_ Inc. - Intellectual Property Security Agreement - RubiconMD, Inc#page6.tif

source=Hercules Capital - Oak Street Health_ Inc. - Intellectual Property Security Agreement - RubiconMD, Inc#page7.tif

source=Hercules Capital - Oak Street Health_ Inc. - Intellectual Property Security Agreement - RubiconMD, Inc#page8.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT (this "Agreement") dated as of September 30, 2022, is made by **RUBICONMD, INC., a Delaware corporation** (the "Grantor"), in favor of HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent (together with its permitted successors and assigns in such capacities, "Agent") for itself and the Lenders (as defined below).

RECITALS

A. The Grantor has entered into a Loan and Security Agreement with certain financial institutions party thereto (the "Lenders") and Agent, dated as of the date hereof (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "Loan Agreement"). All capitalized terms used but not defined herein shall have the respective meanings given to them in the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, the Grantor has granted to Agent for its benefit and the benefit of the Lenders a security interest in all of the Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, the Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. Grant of Security Interest. To secure its obligations under the Loan Agreement, the Grantor grants to Agent for its benefit and the benefit of the Lenders a security interest in all of Grantor's right, title and interest in, to and under its intellectual property (all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, now or hereafter existing, created, acquired or held, including without limitation those registered Copyrights set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to the Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions, re-examination certificates, utility models, and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of the Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(i) All amendments, renewals and extensions of any of the Copyrights, Trademarks, or Patents;
and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing, the Intellectual Property Collateral does not include any property excluded from the Collateral in accordance with Section 3.2 of the Loan Agreement, including, without limitation, any "intent to use" trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, provided, that upon submission and acceptance by the United States Patent and Trademark Office of an amendment to allege use of an intent-to-use trademark application pursuant to 15 U.S.C. Section 1060(a) (or any successor provision) such intent-to-use application shall constitute Collateral.

2. Recordation. The Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Agent.

3. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Agent with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

4. Execution in Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

5. Successors and Assigns. The provisions of this Agreement shall inure to the benefit of the parties hereto and their respective successors and assigns. Except in connection with a transaction permitted by the Loan Agreement, the Grantor shall not assign its obligations under this Agreement without Agent's express prior written consent, and any such attempted assignment shall be void and of no effect. Agent may assign, transfer, or endorse its rights hereunder pursuant to the terms of the Loan Agreement without prior notice to the Grantor, and all of such rights shall inure to the benefit of Agent's successors and assigns.

6. Governing Law. This Agreement has been negotiated and delivered to Agent in the State of New York, and shall have been accepted by Agent in the State of New York. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

7. Electronic Execution of Certain Other Documents. The words "execution," "execute," "signed," "signature," and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity and enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

8. Termination. This Agreement shall terminate and the Lien on and the security interest in the Intellectual Property Collateral shall be released upon the payment in full of the Secured Obligations (other than inchoate obligations, any obligations under Bank Services Agreements for which satisfactory arrangements with the


provider of such Bank Services have been made and any other obligations which, by their terms, are to survive the termination of the Loan Agreement). Upon the termination of this Agreement, Agent shall execute all documents, make all filings, and take all other actions reasonably requested by the Grantor to evidence and record the release of the Lien on and security interests in the Intellectual Property Collateral granted herein.

[Signature page follows.]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

RUBICONMD, INC., a Delaware corporation

DocuSigned by:

By: _____
Name: Timothy Cook
Title: Vice-President and Treasurer

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

RUBICONMD, INC., a Delaware Corporation

By: _____
Name: _____
Title: _____

AGENT:

HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent

By: _____
Name: Seth Meyer
Title: Chief Financial Officer

EXHIBIT A

Registered Copyrights

None.


EXHIBIT B

Patents and Patent Applications

None.

EXHIBIT C

Trademark Registrations and Applications

Mark	Status	App/Reg Number	App/Reg Date
RUBICONMD	Registered	6152085	September 15, 2020
 RubiconMD	Registered	6152085	September 15, 2020
CLINICAL TRANSFORMATION IN TECHNOLOGY	Registered	5820852	July 30, 2019
BHCARE	Pending	97322231	March 21, 2022
ECONSULT+	Pending	97322197	March 21, 2022